AI assistant
Sending…
REPLIGEN CORP — Director's Dealing 2024
Dec 6, 2024
30826_dirs_2024-12-05_8fa1ad07-fdcd-4ce8-91a0-4fee11179a67.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2024-12-05
Reporting Person: Hunt Anthony (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-05 | Common Stock | M | 11808 | $33.87 | Acquired | 151648 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-05 | Stock Option (Right to Buy) | $33.87 | M | 11808 | Acquired | 2028-02-29 | Common Stock (11808) | Direct |
Footnotes
F1: 11,808 of the shares underlying this option have vested. The remaining shares vest as follows: 2,952 shares on March 1, 2025, 2,952 shares on March 1, 2026, and 2,952 shares on March 1, 2027.
More from REPLIGEN CORP
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 5
Proxy Solicitation & Information Statement
2026
Apr 27
Annual Report
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Proxy Solicitation & Information Statement
2026
Apr 2
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 23
Director's Dealing
2026
Mar 23